In the past 12 months Atomo has secured grant funding to commercialise various tests using its technology, including a grant from the NSW Medical Devices Fund for a digital HIV Self-Test and a grant from the Australian Commonwealth for a range of tropical fever tests.
Today we can also announce that the company has raised A$4.5 million in new equity funding from a number of professional investors including the New York-based Global Health Investment Fund (GHIF), as well as a company associated with former Managing Director and CEO of Macquarie Group Limited, Mr. Allan Moss AO.
The new investment follows receipt of a US$6 million (A$7.8 million) loan to Atomo by GHIF in January this year, and sees Global Health Investment Fund Managing Partner Dr. Curt LaBelle join the Atomo board.
Atomo Diagnostics Chairman John Keith said “We are delighted GHIF is now a shareholder. We welcome them to the Board and look forward to working to further expand Atomo’s presence in the global health market.”